This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Lentivirus with baboon retroviral envelope glycoprotein for enhanced hematopoietic stem cell (HSC) therapy	<p>Mouse and <i>in vitro</i> studies suggest lentivirus with the baboon endogenous retrovirus envelope glycoprotein (BaEV) could improve HSC-based therapy. In immunodeficient mice, engraftment of human CD34⁺ HSCs that were transduced <i>ex vivo</i> with BaEV lentivirus resulted in up to 90% of virus-positive cells in recipient mice. In cultures of human CD34⁺ HSCs, low titers of BaEV lentiviruses transduced up to 30% of cells in the absence of cytokines, whereas vesicular stomatitis virus (VSV)-G lentiviruses were unable to infect the cells. Next steps include optimizing production of the vectors according to GMP standards and establishing a stable producer cell line.</p> <p>SciBX 7(30); doi:10.1038/scibx.2014.912 Published online Aug. 7, 2014</p>	Methods covering the production and application of BaEV lentivirus patented; licensed to Lentigen Corp.	<p>Girard-Gagnepain, A. <i>et al. Blood</i>; published online June 20, 2014; doi:10.1182/blood-2014-02-558163</p> <p>Contact: Els Verhoeyen, University of Lyon, Lyon, France e-mail: els.verhoyen@ens-lyon.fr</p>